Jubilant Pharmova profits halved to ₹397 cr as remediation costs weigh

Jubilant Pharmova grew consolidated revenue by 14.5% to ₹82,796 million in FY26. Despite this expansion, net profit collapsed to ₹3,975 million from ₹8,363 million. The decline originates from two distinct pressures: the absence of asset-sale gains that buoyed the prior year and the direct costs of remediating a problematic OAI-status facility in Montreal. The board recommended a dividend of ₹5 per share, signaling a retention of prior payout practices despite the earnings compression. This is a routine annual release that aligns with market expectations. It provides a detailed view of segment operations but offers no unexpected pivots for investors. The core challenge for the company remains the Montreal site; until that regulatory hurdle clears, operational costs will likely continue to mask underlying performance trends.